Friday 6 November 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue: −0.28%
EPS: −154.6%
Free cash flow: +38.8%
Total debt: −89.4%

Quarter to September 2026, against a year earlier

19.71 0.74 +3.90%

Follow VTRS

Alert me

Market cap: $21.8B
P/E: 0.0×
Fwd P/E: 82.6×
Dividend yield: 2.54%
F-score: 4/9
Altman Z: 0.61
Beneish M: −3.29
Dividend safety: 37/100

Overview Business Profile Earnings & Analysis Valuation Filings

Viatris Inc. 10-Q filed Nov 5, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 5, 2026 · accepted 9:23 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 6, 2026: no comparison — the earlier filing's Item cannot be compared